

# Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



# Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

# Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



### **Product** Data Sheet

# Lacto-N-fucopentaose I

Cat. No.: HY-W019806 CAS No.: 7578-25-8 Molecular Formula:  $C_{32}H_{55}NO_{25}$ 

Molecular Weight: 853.77

Target: Endogenous Metabolite; CDK; Reactive Oxygen Species; Apoptosis; Enterovirus;

Bacterial

Pathway: Metabolic Enzyme/Protease; Cell Cycle/DNA Damage; Immunology/Inflammation;

NF-κB; Apoptosis; Anti-infection

Storage: 4°C, protect from light

\* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

#### **BIOLOGICAL ACTIVITY**

**Description** Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity.

Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote CDK2 and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-

N-fucopentaose I can also regulate intestinal microbiota to affect immune system development<sup>[1]</sup>.

IC<sub>50</sub> & Target Human Endogenous CDK2/cyclinE

Metabolite

In Vitro Lacto-N-fucopentaose I (25-3200 μg/mL;48 h) exhibits certain cytotoxicity at 3200 μg/mL but no toxic reaction below 1600 μ

g/mL[1].

Lacto-N-fucopentaose I (25-1600  $\mu$ g/mL; 14-18 h) can protect EV71-infected RD cells from death<sup>[1]</sup>.

Lacto-N-fucopentaose I (100-400  $\mu$ g/mL; 16 h) decreases markedly mRNA levels of VP1 and ROS production in EV71-infected RD cells at 400  $\mu$ g/mL; leads to the recovery of EV71-induced S phase arrest in RD cells<sup>[1]</sup>.

Lacto-N-fucopentaose I (100 and 200  $\mu$ g/mL; 3 days) inhibits cell apoptosis in Caenorhabditis elegans; significantly decreases the levels of Egl-1, Ced-3 and Ced-4<sup>[1]</sup>.

Lacto-N-fucopentaose I can reduce the abundance of Sphingobacterium, Stenotrophomonas and Achromobacter; can increase the abundance of Micromonospora, Vibrio, Acidibacter, Gaiella, Devosia, Steroidobacter, Variibacter, Dactylosporangium, RB41, Pir4\_lineage, Pirellula, Haliangium, Roseiflexus, Pedomicrobium, and Bradyrhizobium.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[1]</sup>

Cell Line:	RD cells
Concentration:	25, 50, 100, 200, 400, 800, 1600 and 3200 μg/mL
Incubation Time:	48 h
Result:	Exhibited certain cytotoxicity at 3200 μg/mL but no toxic reaction below 1600 μg/mL.
RT-PCR <sup>[1]</sup>	
Cell Line:	RD cells (infected with EV71)

Concentration:	100, 200 and 400 μg/mL
Incubation Time:	16 h
Result:	Decreased markedly mRNA levels of VP1 only at 400 μg/mL.
Apoptosis Analysis <sup>[1]</sup>	
Cell Line:	RD cells (infected with EV71)
Concentration:	100, 200 and 400 μg/mL
Incubation Time:	16 h
Result:	Decreased the rate of cells in early apoptosis to $10.9\% \pm 1.26\%$ at $400 \mu g/mL$ , while the untreated EV71 group was $27.7\% \pm 2.13\%$ . Significantly inhibited the activity of caspase-3, caspase-8 and caspase-9. Recovered the decreased mRNA expression of PAPR, NF- $\kappa$ B and Bcl-2 and properly regulated Bad and Fas into their normal levels.
Cell Cycle Analysis <sup>[1]</sup>	
Cell Line:	RD cells (infected with EV71)
Concentration:	100, 200 and 400 μg/mL
Incubation Time:	12 h
Result:	Rescued EV71-induced S phase arrest, which promoted the transition of the G1 phase to the S phase.

#### **REFERENCES**

[1]. Gao X, et al. Fucosylated oligosaccharide Lacto-N-fucopentaose I ameliorates enterovirus 71 infection by inhibiting apoptosis. Food Chem X. 2022 Feb 4;13:100244.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA